JP5531367B2 - 標的配列の濃縮 - Google Patents
標的配列の濃縮 Download PDFInfo
- Publication number
- JP5531367B2 JP5531367B2 JP2010519925A JP2010519925A JP5531367B2 JP 5531367 B2 JP5531367 B2 JP 5531367B2 JP 2010519925 A JP2010519925 A JP 2010519925A JP 2010519925 A JP2010519925 A JP 2010519925A JP 5531367 B2 JP5531367 B2 JP 5531367B2
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- target
- reference sequence
- duplex
- pcr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 claims description 199
- 150000007523 nucleic acids Chemical class 0.000 claims description 142
- 102000039446 nucleic acids Human genes 0.000 claims description 111
- 108020004707 nucleic acids Proteins 0.000 claims description 111
- 238000004925 denaturation Methods 0.000 claims description 93
- 230000036425 denaturation Effects 0.000 claims description 92
- 108700028369 Alleles Proteins 0.000 claims description 83
- 239000000523 sample Substances 0.000 claims description 77
- 238000006243 chemical reaction Methods 0.000 claims description 66
- 125000003729 nucleotide group Chemical group 0.000 claims description 61
- 239000002773 nucleotide Substances 0.000 claims description 59
- 239000011541 reaction mixture Substances 0.000 claims description 57
- 238000012163 sequencing technique Methods 0.000 claims description 51
- 238000002844 melting Methods 0.000 claims description 45
- 238000003753 real-time PCR Methods 0.000 claims description 40
- 238000001514 detection method Methods 0.000 claims description 35
- 230000008018 melting Effects 0.000 claims description 34
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 claims description 25
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 claims description 20
- 230000015572 biosynthetic process Effects 0.000 claims description 15
- 238000012217 deletion Methods 0.000 claims description 13
- 230000037430 deletion Effects 0.000 claims description 13
- 238000007847 digital PCR Methods 0.000 claims description 11
- 238000003780 insertion Methods 0.000 claims description 10
- 230000037431 insertion Effects 0.000 claims description 10
- 238000012175 pyrosequencing Methods 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 101000829171 Hypocrea virens (strain Gv29-8 / FGSC 10586) Effector TSP1 Proteins 0.000 claims description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 2
- 230000035772 mutation Effects 0.000 description 127
- 108020004414 DNA Proteins 0.000 description 117
- 238000003752 polymerase chain reaction Methods 0.000 description 114
- 239000013615 primer Substances 0.000 description 104
- 238000003199 nucleic acid amplification method Methods 0.000 description 80
- 230000003321 amplification Effects 0.000 description 79
- 206010028980 Neoplasm Diseases 0.000 description 45
- 238000009396 hybridization Methods 0.000 description 42
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 40
- 210000004027 cell Anatomy 0.000 description 35
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 33
- 108091028043 Nucleic acid sequence Proteins 0.000 description 28
- 239000012634 fragment Substances 0.000 description 27
- 239000000047 product Substances 0.000 description 26
- 108091034117 Oligonucleotide Proteins 0.000 description 22
- 238000000137 annealing Methods 0.000 description 22
- 206010069754 Acquired gene mutation Diseases 0.000 description 21
- 230000037439 somatic mutation Effects 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 19
- 239000000975 dye Substances 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 15
- 230000000295 complement effect Effects 0.000 description 14
- 229920002477 rna polymer Polymers 0.000 description 14
- 102000054765 polymorphisms of proteins Human genes 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 239000003960 organic solvent Substances 0.000 description 12
- 230000002441 reversible effect Effects 0.000 description 12
- 239000000872 buffer Substances 0.000 description 11
- 238000004422 calculation algorithm Methods 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 11
- 230000008859 change Effects 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 210000002381 plasma Anatomy 0.000 description 11
- 102000053602 DNA Human genes 0.000 description 10
- 230000008901 benefit Effects 0.000 description 10
- 238000011897 real-time detection Methods 0.000 description 10
- 238000007480 sanger sequencing Methods 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- 239000001046 green dye Substances 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 102000040430 polynucleotide Human genes 0.000 description 9
- 108091033319 polynucleotide Proteins 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 8
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 8
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000001605 fetal effect Effects 0.000 description 8
- 239000002157 polynucleotide Substances 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 239000003155 DNA primer Substances 0.000 description 7
- 101150105104 Kras gene Proteins 0.000 description 7
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 238000004364 calculation method Methods 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 230000029087 digestion Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000007850 fluorescent dye Substances 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 108091093037 Peptide nucleic acid Proteins 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 5
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 5
- 210000004602 germ cell Anatomy 0.000 description 5
- 238000011880 melting curve analysis Methods 0.000 description 5
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 108091093088 Amplicon Proteins 0.000 description 4
- 108020000946 Bacterial DNA Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 108091092878 Microsatellite Proteins 0.000 description 4
- 108020005202 Viral DNA Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 239000003184 complementary RNA Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 238000003205 genotyping method Methods 0.000 description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 4
- 238000009830 intercalation Methods 0.000 description 4
- 230000011987 methylation Effects 0.000 description 4
- 238000007069 methylation reaction Methods 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 230000007704 transition Effects 0.000 description 4
- 229940035893 uracil Drugs 0.000 description 4
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 3
- 108020004394 Complementary RNA Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 201000005249 lung adenocarcinoma Diseases 0.000 description 3
- 238000007403 mPCR Methods 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 230000008774 maternal effect Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000003068 molecular probe Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- -1 nucleoside triphosphates Chemical class 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000002987 primer (paints) Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 241000238557 Decapoda Species 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 108091027305 Heteroduplex Proteins 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 206010069755 K-ras gene mutation Diseases 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000012252 genetic analysis Methods 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 208000037841 lung tumor Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000007857 nested PCR Methods 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- NOIRDLRUNWIUMX-UHFFFAOYSA-N 2-amino-3,7-dihydropurin-6-one;6-amino-1h-pyrimidin-2-one Chemical compound NC=1C=CNC(=O)N=1.O=C1NC(N)=NC2=C1NC=N2 NOIRDLRUNWIUMX-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- ZLSOONVQLWLPMF-UHFFFAOYSA-M 3-(3,8-diamino-6-phenylphenanthridin-5-ium-5-yl)propyl-diethyl-methylazanium;dibromide Chemical compound [Br-].[Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 ZLSOONVQLWLPMF-UHFFFAOYSA-M 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- LOSIULRWFAEMFL-UHFFFAOYSA-N 7-deazaguanine Chemical compound O=C1NC(N)=NC2=C1CC=N2 LOSIULRWFAEMFL-UHFFFAOYSA-N 0.000 description 1
- VKKXEIQIGGPMHT-UHFFFAOYSA-N 7h-purine-2,8-diamine Chemical class NC1=NC=C2NC(N)=NC2=N1 VKKXEIQIGGPMHT-UHFFFAOYSA-N 0.000 description 1
- 208000035657 Abasia Diseases 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 108010007577 Exodeoxyribonuclease I Proteins 0.000 description 1
- 102100029075 Exonuclease 1 Human genes 0.000 description 1
- 210000000712 G cell Anatomy 0.000 description 1
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 1
- 108010022901 Heparin Lyase Proteins 0.000 description 1
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 229930182474 N-glycoside Natural products 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 241000205156 Pyrococcus furiosus Species 0.000 description 1
- 101150040459 RAS gene Proteins 0.000 description 1
- 101150076031 RAS1 gene Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 241000589596 Thermus Species 0.000 description 1
- 108010085671 Thermus thermophilus DNA polymerase Proteins 0.000 description 1
- 108010001244 Tli polymerase Proteins 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- GRRMZXFOOGQMFA-UHFFFAOYSA-J YoYo-1 Chemical compound [I-].[I-].[I-].[I-].C12=CC=CC=C2C(C=C2N(C3=CC=CC=C3O2)C)=CC=[N+]1CCC[N+](C)(C)CCC[N+](C)(C)CCC[N+](C1=CC=CC=C11)=CC=C1C=C1N(C)C2=CC=CC=C2O1 GRRMZXFOOGQMFA-UHFFFAOYSA-J 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000007846 asymmetric PCR Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000007419 epigenetic assay Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000001869 matrix assisted laser desorption--ionisation mass spectrum Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000001531 micro-dissection Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- VMCOQLKKSNQANE-UHFFFAOYSA-N n,n-dimethyl-4-[6-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-benzimidazol-2-yl]aniline Chemical compound C1=CC(N(C)C)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 VMCOQLKKSNQANE-UHFFFAOYSA-N 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000037048 polymerization activity Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- IGFXRKMLLMBKSA-UHFFFAOYSA-N purine Chemical compound N1=C[N]C2=NC=NC2=C1 IGFXRKMLLMBKSA-UHFFFAOYSA-N 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6848—Nucleic acid amplification reactions characterised by the means for preventing contamination or increasing the specificity or sensitivity of an amplification reaction
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96283807P | 2007-08-01 | 2007-08-01 | |
| US60/962,838 | 2007-08-01 | ||
| PCT/US2008/009248 WO2009017784A2 (en) | 2007-08-01 | 2008-07-31 | Enrichment of a target sequence |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010535031A JP2010535031A (ja) | 2010-11-18 |
| JP2010535031A5 JP2010535031A5 (enExample) | 2013-08-08 |
| JP5531367B2 true JP5531367B2 (ja) | 2014-06-25 |
Family
ID=40305136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010519925A Expired - Fee Related JP5531367B2 (ja) | 2007-08-01 | 2008-07-31 | 標的配列の濃縮 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8455190B2 (enExample) |
| EP (1) | EP2183379B1 (enExample) |
| JP (1) | JP5531367B2 (enExample) |
| KR (1) | KR101376359B1 (enExample) |
| CN (1) | CN101815789B (enExample) |
| AU (1) | AU2008282780B2 (enExample) |
| CA (1) | CA2695264C (enExample) |
| DK (1) | DK2183379T3 (enExample) |
| ES (1) | ES2547053T3 (enExample) |
| PT (1) | PT2183379E (enExample) |
| WO (1) | WO2009017784A2 (enExample) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9424392B2 (en) | 2005-11-26 | 2016-08-23 | Natera, Inc. | System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals |
| US11111544B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
| WO2008105814A2 (en) | 2006-08-22 | 2008-09-04 | Los Alamos National Security, Llc | Miniturized lateral flow device for rapid and sensitive detection of proteins or nucleic acids |
| US8980561B1 (en) | 2006-08-22 | 2015-03-17 | Los Alamos National Security, Llc. | Nucleic acid detection system and method for detecting influenza |
| CN101903535A (zh) | 2007-03-28 | 2010-12-01 | 信号诊断公司 | 高解析度分析核酸以检测序列变异的系统和方法 |
| KR101376359B1 (ko) | 2007-08-01 | 2014-03-27 | 다나-파버 캔서 인스티튜트 인크. | 표적 서열 강화 |
| EP2279403B1 (en) | 2008-05-05 | 2016-03-16 | Los Alamos National Security, LLC | Highly simplified lateral flow-based nucleic acid sample preparation and passive fluid flow control |
| US10669574B2 (en) | 2008-11-18 | 2020-06-02 | XCR Diagnostics, Inc. | DNA amplification technology |
| JP5795341B2 (ja) * | 2010-03-08 | 2015-10-14 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 参照ブロック配列によるｆｕｌｌＣＯＬＤ−ＰＣＲ濃縮 |
| KR101312241B1 (ko) * | 2010-04-27 | 2013-09-27 | 사회복지법인 삼성생명공익재단 | 증폭억제시발체를 이용하는 유전자 돌연변이 검출 방법 |
| US11339429B2 (en) | 2010-05-18 | 2022-05-24 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US11408031B2 (en) | 2010-05-18 | 2022-08-09 | Natera, Inc. | Methods for non-invasive prenatal paternity testing |
| US11322224B2 (en) | 2010-05-18 | 2022-05-03 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US20190010543A1 (en) | 2010-05-18 | 2019-01-10 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US10316362B2 (en) | 2010-05-18 | 2019-06-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US11332793B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US12152275B2 (en) | 2010-05-18 | 2024-11-26 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US11332785B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US9677118B2 (en) | 2014-04-21 | 2017-06-13 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US11939634B2 (en) | 2010-05-18 | 2024-03-26 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US8825412B2 (en) | 2010-05-18 | 2014-09-02 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US11326208B2 (en) | 2010-05-18 | 2022-05-10 | Natera, Inc. | Methods for nested PCR amplification of cell-free DNA |
| US12221653B2 (en) | 2010-05-18 | 2025-02-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| CA2824387C (en) | 2011-02-09 | 2019-09-24 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| KR20140010093A (ko) * | 2011-02-28 | 2014-01-23 | 트랜스제노믹, 인크. | 혼합 집단 중 표적 dna의 서열분석을 위한 키트 및 방법 |
| ITTO20110271A1 (it) | 2011-03-28 | 2012-09-29 | Fabio Gentilini | Metodo per l'identificazione di polimorfismi genetici di base singola. |
| EP2691541B1 (en) * | 2011-03-31 | 2017-10-18 | Dana-Farber Cancer Institute, Inc. | Method for enriching in single-stranded mutant sequences from mixture of wild-type and mutant sequences |
| ES2583135T3 (es) | 2011-04-20 | 2016-09-19 | Mesa Biotech, Inc. | Dispositivo integrado para la detección e identificación de ácidos nucleicos |
| WO2012151328A2 (en) | 2011-05-02 | 2012-11-08 | President And Fellows Of Harvard College | Spatial sequestration of dynamic nucleic acid circuits |
| US9617392B2 (en) | 2011-07-10 | 2017-04-11 | President And Fellows Of Harvard College | Compositions and methods for self-assembly of polymers with complementary macroscopic and microscopic scale units |
| EP2744916A4 (en) | 2011-07-13 | 2015-06-17 | Primeradx Inc | MULTIMODAL PROCEDURE FOR THE SIMULTANEOUS DETECTION AND QUANTIFICATION OF MULTIPLE NUCLEIC ACIDS IN ONE SAMPLE |
| US9074247B2 (en) * | 2011-10-06 | 2015-07-07 | Drexel University | P53 assay for a urine test for HCC screening |
| CN103998921B (zh) | 2011-10-14 | 2016-04-20 | 贝克顿·迪金森公司 | 方波热循环 |
| US9133490B2 (en) | 2012-05-16 | 2015-09-15 | Transgenomic, Inc. | Step-up method for COLD-PCR enrichment |
| CN104350161A (zh) * | 2012-06-14 | 2015-02-11 | 弗莱德哈钦森癌症研究中心 | 用于核酸分子中的敏感突变检测的组合物和方法 |
| US20140100126A1 (en) | 2012-08-17 | 2014-04-10 | Natera, Inc. | Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data |
| US9732390B2 (en) | 2012-09-20 | 2017-08-15 | The Chinese University Of Hong Kong | Non-invasive determination of methylome of fetus or tumor from plasma |
| US10706957B2 (en) | 2012-09-20 | 2020-07-07 | The Chinese University Of Hong Kong | Non-invasive determination of methylome of tumor from plasma |
| WO2015013166A1 (en) * | 2013-07-24 | 2015-01-29 | Dana-Farber Cancer Institute, Inc. | Methods and compositions to enable enrichment of minor dna alleles by limiting denaturation time in pcr or simply enable enrichment of minor dna alleles by limiting denaturation time in pcr |
| ES2925313T3 (es) | 2013-10-09 | 2022-10-14 | Fluoresentric Inc | Método para la detección de secuencias de ácido nucleico diana |
| US20160273022A1 (en) * | 2013-10-20 | 2016-09-22 | Trovagene, Inc. | Synthesis and enrichment of nucleic acid sequences |
| CA2922261A1 (en) * | 2013-10-20 | 2015-05-21 | Trovagene, Inc. | Synthesis and enrichment of nucleic acid sequences |
| CN103602748A (zh) * | 2013-11-28 | 2014-02-26 | 瑞希基因科技（北京）股份有限公司 | 一种结合荧光定量pcr技术的焦磷酸测序方法 |
| EP3957749A1 (en) | 2014-04-21 | 2022-02-23 | Natera, Inc. | Detecting tumour specific mutations in biopsies with whole exome sequencing and in cell-free samples |
| US12492429B2 (en) | 2014-04-21 | 2025-12-09 | Natera, Inc. | Detecting mutations and ploidy in chromosomal segments |
| US20180173846A1 (en) | 2014-06-05 | 2018-06-21 | Natera, Inc. | Systems and Methods for Detection of Aneuploidy |
| KR102295290B1 (ko) * | 2014-07-10 | 2021-08-30 | 플루어레센트릭 인코포레이티드 | Dna 증폭 기술 |
| TWI895765B (zh) | 2014-07-18 | 2025-09-01 | 香港中文大學 | Dna混合物中之組織甲基化模式分析 |
| WO2016172724A1 (en) | 2015-04-24 | 2016-10-27 | Mesa Biotech, Inc. | Fluidic test cassette |
| US11479812B2 (en) | 2015-05-11 | 2022-10-25 | Natera, Inc. | Methods and compositions for determining ploidy |
| HUE048349T2 (hu) * | 2015-05-18 | 2020-07-28 | Saga Diagnostics Ab | Célnukleinsavak és variánsok detektálása |
| WO2016190897A1 (en) * | 2015-05-27 | 2016-12-01 | Quest Diagnostics Investments Incorporated | Compositions and methods for screening solid tumors |
| WO2017070339A1 (en) * | 2015-10-20 | 2017-04-27 | Richardson Katherine | Microfluidic device for enrichment of nucleic acid sequence alterations |
| JP7280044B2 (ja) | 2016-04-15 | 2023-05-23 | ナテラ， インコーポレイテッド | 肺癌の検出方法 |
| WO2018067517A1 (en) | 2016-10-04 | 2018-04-12 | Natera, Inc. | Methods for characterizing copy number variation using proximity-litigation sequencing |
| GB201618485D0 (en) | 2016-11-02 | 2016-12-14 | Ucl Business Plc | Method of detecting tumour recurrence |
| IL315032A (en) | 2016-11-30 | 2024-10-01 | Univ Hong Kong Chinese | Analysis of cell-free dna in urine and other samples |
| US10011870B2 (en) | 2016-12-07 | 2018-07-03 | Natera, Inc. | Compositions and methods for identifying nucleic acid molecules |
| CA3046953A1 (en) | 2016-12-12 | 2018-06-21 | Dana Farber Cancer Institute, Inc. | Compositions and methods for molecular barcoding of dna molecules prior to mutation enrichment and/or mutation detection |
| WO2019023243A1 (en) | 2017-07-24 | 2019-01-31 | Dana-Farber Cancer Institute, Inc. | METHODS AND COMPOSITIONS FOR SELECTING AND AMPLIFYING DNA TARGETS IN A SINGLE REACTION MIXTURE |
| WO2019099420A1 (en) * | 2017-11-15 | 2019-05-23 | Yan Wang | A method for detecting multiple dna mutations and copy number variations |
| WO2019118926A1 (en) | 2017-12-14 | 2019-06-20 | Tai Diagnostics, Inc. | Assessing graft suitability for transplantation |
| DE202019005627U1 (de) | 2018-04-02 | 2021-05-31 | Grail, Inc. | Methylierungsmarker und gezielte Methylierungssondenpanels |
| US12024738B2 (en) | 2018-04-14 | 2024-07-02 | Natera, Inc. | Methods for cancer detection and monitoring |
| US12234509B2 (en) | 2018-07-03 | 2025-02-25 | Natera, Inc. | Methods for detection of donor-derived cell-free DNA |
| GB201812192D0 (en) | 2018-07-26 | 2018-09-12 | Ttp Plc | Variable temperature reactor, heater and control circuit for the same |
| JP6544783B1 (ja) | 2018-07-31 | 2019-07-17 | 学校法人 岩手医科大学 | がんの診断のためのプローブ／プライマーライブラリー |
| AU2019351130B2 (en) | 2018-09-27 | 2025-10-23 | GRAIL, Inc | Methylation markers and targeted methylation probe panel |
| WO2020247263A1 (en) | 2019-06-06 | 2020-12-10 | Natera, Inc. | Methods for detecting immune cell dna and monitoring immune system |
| EP4017998B1 (en) | 2019-08-21 | 2024-11-06 | Dana-Farber Cancer Institute, Inc. | Multi-site enrichment of deletions in dna microsatellites |
| US11866793B2 (en) | 2020-03-27 | 2024-01-09 | Regents Of The University Of Minnesota | Assay for detecting palmer amaranth DNA in individual and mixed samples |
| EP4624573A1 (en) | 2022-11-22 | 2025-10-01 | Quantdetect, Inc. | Probe/primer library for cancer diagnosis |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| US5310652A (en) | 1986-08-22 | 1994-05-10 | Hoffman-La Roche Inc. | Reverse transcription with thermostable DNA polymerase-high temperature reverse transcription |
| CA1340807C (en) | 1988-02-24 | 1999-11-02 | Lawrence T. Malek | Nucleic acid amplification process |
| GB2228086A (en) | 1988-11-25 | 1990-08-15 | Ici Plc | Characterisation of genomic DNA |
| KR920700360A (ko) | 1989-03-22 | 1992-02-19 | 하리크 프리드리히 | 미끄럼 베어링 |
| US5075217A (en) | 1989-04-21 | 1991-12-24 | Marshfield Clinic | Length polymorphisms in (dC-dA)n ·(dG-dT)n sequences |
| AU5645690A (en) | 1989-05-05 | 1990-11-29 | Lifecodes Corporation | Method for genetic analysis of a nucleic acid sample |
| CA2020958C (en) | 1989-07-11 | 2005-01-11 | Daniel L. Kacian | Nucleic acid sequence amplification methods |
| US5045450A (en) * | 1989-07-13 | 1991-09-03 | Massachusetts Institute Of Technology | Determination of a mutational spectrum |
| DE3938907C2 (de) | 1989-11-24 | 1999-11-04 | Dade Behring Marburg Gmbh | Mittel zum Lagern und Suspendieren von Zellen, insbesondere Erythrozyten |
| US5427930A (en) | 1990-01-26 | 1995-06-27 | Abbott Laboratories | Amplification of target nucleic acids using gap filling ligase chain reaction |
| KR950013953B1 (ko) | 1990-01-26 | 1995-11-18 | 애보트 래보라토리즈 | 리가제 연쇄 반응에 적용가능한 표적 핵산의 증폭 방법 |
| EP0516753A4 (en) | 1990-02-26 | 1994-05-18 | Us Health | A method for the fluorescent detection of a dna sequence in real time |
| WO1991014003A2 (en) | 1990-03-09 | 1991-09-19 | Ig Laboratories, Inc. | Characterization and analysis of polymorphic vntr loci |
| US5846710A (en) | 1990-11-02 | 1998-12-08 | St. Louis University | Method for the detection of genetic diseases and gene sequence variations by single nucleotide primer extension |
| US5648211A (en) | 1994-04-18 | 1997-07-15 | Becton, Dickinson And Company | Strand displacement amplification using thermophilic enzymes |
| US5631147A (en) | 1995-09-21 | 1997-05-20 | Becton, Dickinson And Company | Detection of nucleic acids in cells by thermophilic strand displacement amplification |
| ATE199572T1 (de) | 1995-11-21 | 2001-03-15 | Univ Yale | Unimolekulare segmentamplifikation und bestimmung |
| US5849497A (en) | 1997-04-03 | 1998-12-15 | The Research Foundation Of State University Of New York | Specific inhibition of the polymerase chain reaction using a non-extendable oligonucleotide blocker |
| JP3785517B2 (ja) | 1997-06-05 | 2006-06-14 | 東ソー株式会社 | 核酸融解温度測定法 |
| AU9063398A (en) | 1997-09-12 | 1999-04-05 | Exiqon A/S | Oligonucleotide analogues |
| US6174680B1 (en) | 1998-12-30 | 2001-01-16 | Dana-Farber Cancer Institute, Inc. | Method for identifying mismatch repair glycosylase reactive sites, compounds and uses thereof |
| US6850846B2 (en) * | 2000-01-11 | 2005-02-01 | Affymetrix, Inc. | Computer software for genotyping analysis using pattern recognition |
| US6762049B2 (en) * | 2001-07-05 | 2004-07-13 | Institute Of Microelectronics | Miniaturized multi-chamber thermal cycler for independent thermal multiplexing |
| AUPS076902A0 (en) * | 2002-02-26 | 2002-03-21 | Commonwealth Scientific And Industrial Research Organisation | Novel selective polymerase chain reaction |
| CN100334223C (zh) * | 2002-12-18 | 2007-08-29 | 徐定邦 | 一种超低变性温度的聚合酶链式反应方法及其应用 |
| AU2003289651A1 (en) * | 2002-12-18 | 2004-07-09 | Dingbang Xu | Pcr method and application by transnormal low thermo-denaturation temperature |
| US7456281B2 (en) * | 2005-04-20 | 2008-11-25 | Idaho Technology, Inc. | Nucleic acid melting analysis with saturation dyes |
| US20070000020A1 (en) * | 2005-06-30 | 2007-01-04 | Kimberly-Clark Worldwide, Inc. | Surgical glove with modified frictional interface and method for producing same |
| US20070154892A1 (en) * | 2005-12-30 | 2007-07-05 | Simon Wain-Hobson | Differential amplification of mutant nucleic acids by PCR in a mixure of nucleic acids |
| EP2395113A1 (en) * | 2007-06-29 | 2011-12-14 | Population Genetics Technologies Ltd. | Methods and compositions for isolating nucleic acid sequence variants |
| KR101376359B1 (ko) | 2007-08-01 | 2014-03-27 | 다나-파버 캔서 인스티튜트 인크. | 표적 서열 강화 |
| US8071338B2 (en) | 2007-08-08 | 2011-12-06 | Roche Molecular Systems, Inc. | Suppression of amplification using an oligonucleotide and a polymerase significantly lacking 5′-3′ nuclease activity |
-
2008
- 2008-07-31 KR KR1020107004305A patent/KR101376359B1/ko not_active Expired - Fee Related
- 2008-07-31 EP EP08794916.0A patent/EP2183379B1/en active Active
- 2008-07-31 WO PCT/US2008/009248 patent/WO2009017784A2/en not_active Ceased
- 2008-07-31 AU AU2008282780A patent/AU2008282780B2/en not_active Ceased
- 2008-07-31 JP JP2010519925A patent/JP5531367B2/ja not_active Expired - Fee Related
- 2008-07-31 US US12/671,295 patent/US8455190B2/en not_active Expired - Fee Related
- 2008-07-31 CA CA2695264A patent/CA2695264C/en not_active Expired - Fee Related
- 2008-07-31 PT PT87949160T patent/PT2183379E/pt unknown
- 2008-07-31 DK DK08794916.0T patent/DK2183379T3/en active
- 2008-07-31 CN CN2008801098230A patent/CN101815789B/zh active Active
- 2008-07-31 ES ES08794916.0T patent/ES2547053T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2183379A2 (en) | 2010-05-12 |
| DK2183379T3 (en) | 2015-07-27 |
| CN101815789B (zh) | 2013-06-12 |
| ES2547053T3 (es) | 2015-10-01 |
| EP2183379B1 (en) | 2015-04-15 |
| AU2008282780B2 (en) | 2014-04-17 |
| CN101815789A (zh) | 2010-08-25 |
| KR20100044870A (ko) | 2010-04-30 |
| CA2695264A1 (en) | 2009-02-05 |
| CA2695264C (en) | 2015-01-27 |
| JP2010535031A (ja) | 2010-11-18 |
| AU2008282780A1 (en) | 2009-02-05 |
| WO2009017784A3 (en) | 2009-03-26 |
| PT2183379E (pt) | 2015-09-25 |
| US20100203532A1 (en) | 2010-08-12 |
| EP2183379A4 (en) | 2011-08-10 |
| WO2009017784A2 (en) | 2009-02-05 |
| US8455190B2 (en) | 2013-06-04 |
| KR101376359B1 (ko) | 2014-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5531367B2 (ja) | 標的配列の濃縮 | |
| US12077811B2 (en) | Compositions of toehold primer duplexes and methods of use | |
| JP5235905B2 (ja) | 核酸配列の検出方法 | |
| CN101381766B (zh) | 一种基因稀有突变的定量检测方法 | |
| JP2019004914A (ja) | ブロッキングオリゴヌクレオチドを用いたｄｎａ増幅の方法 | |
| US11834707B2 (en) | Nucleic acid amplification blocker for detecting low-abundance mutation sequence and application thereof | |
| KR102371222B1 (ko) | 표적핵산 증폭방법 및 표적핵산 증폭용 조성물 | |
| KR20100063050A (ko) | 디지털 ｐｃｒ에 의한 다양한 길이의 핵산의 분석 | |
| US20030180758A1 (en) | Detection of microsatellite instability and its use in diagnosis of tumors | |
| JP3844996B2 (ja) | 反復性ｐｃｒ産物の融解曲線解析方法 | |
| KR20140010093A (ko) | 혼합 집단 중 표적 dna의 서열분석을 위한 키트 및 방법 | |
| JP2021513858A (ja) | マイクロサテライト不安定性の改善された検出 | |
| CN113122636A (zh) | 检测dna甲基化的试剂及用途 | |
| JP2003518951A (ja) | 多型核酸配列の同時増幅およびリアルタイム検出のための方法 | |
| JP2023505398A (ja) | 対立遺伝子の区分性を高めるｐｃｒ方法及びｐｃｒキット | |
| JP2025118633A (ja) | 高い特異度の標的核酸増幅方法及びこれを利用した標的核酸増幅用組成物 | |
| KR102575618B1 (ko) | 가이드 프로브 및 클램핑 프로브를 이용한 표적핵산 증폭방법 및 이를 포함하는 표적핵산 증폭용 조성물 | |
| CN117487891A (zh) | 一种多片段多位点的基因点突变检测方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110713 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110714 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130530 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20130531 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130614 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20130621 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130708 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130930 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131204 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131224 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140206 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140310 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140404 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5531367 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |